n-methyl-3,4-methylenedioxyamphetamine has been researched along with Adverse Drug Event in 14 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective." | 3.01 | MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. ( Amar, S; Amiaz, R; Bogenschutz, M; Brown, R; Carlin, S; Coker, A; de Boer, A; Doblin, R; Emerson, A; Garas, W; Gelfand, Y; Gorman, I; Hamilton, S; Hapke, E; Harrison, C; Klaire, SS; Kleiman, S; Lilienstein, A; Marta, C; Matthews, R; Mitchell, JM; Mithoefer, A; Mithoefer, M; Nicholas, C; Ot'alora G, M; Paleos, C; Parker-Guilbert, K; Poulter, B; Quevedo, S; Shannon, S; Tzarfaty, K; van der Kolk, B; Wallach, Y; Wang, JB; Wells, G; Woolley, JD; Worthy, R; Yazar-Klosinski, B, 2021) |
| " Many studies introduce statistical errors by inconsistently dichotomizing and comparing light and heavy ecstasy users, making dose-response relationships inconclusive." | 2.61 | The spurious relationship between ecstasy use and neurocognitive deficits: A Bradford Hill review. ( Amoroso, T, 2019) |
| "Besides smoking, alcohol abuse has also been implicated as a renal risk factor." | 2.41 | [Adverse renal effects of legal and illicit drugs]. ( Orth, SR, 2002) |
| " This review discusses both the short- and long-term effects of 3,4-methylenedioxy-methamphetamine including methods by which some of these adverse effects can be prevented or even reversed to increase the safety of the commonly used drug." | 1.48 | Is the recreational use of 3,4-methylenedioxy-methamphetamine safe? ( Boote, T, 2018) |
| "Increased risk of ventricular septal defect was found to be associated with consumption of cough and cold remedies [pre-conception OR 2." | 1.32 | A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England. ( Bateman, DN; Dickinson, D; Matthews, JN; McElhatton, PR; O'Keeffe, M; Thomas, SH; Wren, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Palamar, JJ | 1 |
| Cohen, IV | 1 |
| Makunts, T | 1 |
| Abagyan, R | 1 |
| Thomas, K | 1 |
| Mitchell, JM | 1 |
| Bogenschutz, M | 1 |
| Lilienstein, A | 1 |
| Harrison, C | 1 |
| Kleiman, S | 1 |
| Parker-Guilbert, K | 1 |
| Ot'alora G, M | 1 |
| Garas, W | 1 |
| Paleos, C | 1 |
| Gorman, I | 1 |
| Nicholas, C | 1 |
| Mithoefer, M | 1 |
| Carlin, S | 1 |
| Poulter, B | 1 |
| Mithoefer, A | 1 |
| Quevedo, S | 1 |
| Wells, G | 1 |
| Klaire, SS | 1 |
| van der Kolk, B | 1 |
| Tzarfaty, K | 1 |
| Amiaz, R | 1 |
| Worthy, R | 1 |
| Shannon, S | 1 |
| Woolley, JD | 1 |
| Marta, C | 1 |
| Gelfand, Y | 1 |
| Hapke, E | 1 |
| Amar, S | 1 |
| Wallach, Y | 1 |
| Brown, R | 1 |
| Hamilton, S | 1 |
| Wang, JB | 1 |
| Coker, A | 1 |
| Matthews, R | 1 |
| de Boer, A | 1 |
| Yazar-Klosinski, B | 1 |
| Emerson, A | 1 |
| Doblin, R | 1 |
| Boote, T | 1 |
| Davies, N | 1 |
| English, W | 1 |
| Grundlingh, J | 1 |
| Amoroso, T | 1 |
| Wood, DM | 1 |
| Greene, SL | 1 |
| Dargan, PI | 1 |
| Bateman, DN | 1 |
| McElhatton, PR | 1 |
| Dickinson, D | 1 |
| Wren, C | 1 |
| Matthews, JN | 1 |
| O'Keeffe, M | 1 |
| Thomas, SH | 1 |
| Tanner-Smith, EE | 1 |
| Nutt, DJ | 1 |
| Parrott, AC | 1 |
| Vollenweider, FX | 1 |
| Jones, RT | 1 |
| Baggott, MJ | 1 |
| Yuan, J | 1 |
| Cord, BJ | 1 |
| McCann, UD | 1 |
| Callahan, BT | 1 |
| Ricaurte, GA | 1 |
| Orth, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study[NCT05783817] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder[NCT03537014] | Phase 3 | 100 participants (Actual) | Interventional | 2018-11-21 | Completed | ||
| A Randomized, Double-Blind, Single-Site Phase II 2-Arm Study to Compare the Safety and Preliminary Efficacy of Manualized MDMA-Assisted Therapy to Low Dose D-Amphetamine Assisted Therapy in Veterans For The Treatment of Moderate to Severe PTSD[NCT05790239] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| MDMA-Assisted Therapy 6 to 12 Months After Childbirth for People With Co-occurring Opioid Use and Post Traumatic Stress Disorders[NCT05219175] | Phase 2 | 15 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Clinician-Administered PTSD Scale for DSM-V (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT03537014)
Timeframe: Baseline to 18 weeks post enrollment confirmation
| Intervention | score on a scale (Mean) |
|---|---|
| MDMA-assisted Therapy | -24.4 |
| Placebo With Therapy | -13.9 |
The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment that was adapted for the purposes of this study to limit missing item-level data as per the FDA requirements and included use of the three-item mean as the total score and imputation of work-related impairment. The SDS is a 3-item scale measuring the severity of disability in the domains of work, family life/home responsibilities and social/leisure activities, with each item scored on a ten-point Likert scale from 0 ('not at all impaired') to 10 ('very severely impaired'). The SDS total score was the mean of the 3 item responses. The SDS total score ranged from 0 to 10, with higher scores indicating greater functional impairment. (NCT03537014)
Timeframe: Baseline to 18 weeks post enrollment confirmation
| Intervention | score on a scale (Mean) |
|---|---|
| MDMA-assisted Therapy | -3.1 |
| Placebo With Therapy | -2.0 |
3 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Adverse Drug Event
| Article | Year |
|---|---|
MDMA toxicity: management of acute and life-threatening presentations.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxya | 2018 |
The spurious relationship between ecstasy use and neurocognitive deficits: A Bradford Hill review.
Topics: Cognition; Databases, Bibliographic; Drug-Related Side Effects and Adverse Reactions; Humans; Memory | 2019 |
[Adverse renal effects of legal and illicit drugs].
Topics: Acute Kidney Injury; Adolescent; Adult; Alcoholism; Amphetamines; Anti-Anxiety Agents; Benzodiazepin | 2002 |
1 trial available for n-methyl-3,4-methylenedioxyamphetamine and Adverse Drug Event
| Article | Year |
|---|---|
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
10 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Adverse Drug Event
| Article | Year |
|---|---|
Adverse drug effects as a deterrent against willingness to use in the future among nightclub/festival attendees.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Holidays; Humans; Illicit Drugs; Ketamine; M | 2023 |
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Cause of Death; Databases, Factual; | 2021 |
Is the recreational use of 3,4-methylenedioxy-methamphetamine safe?
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxya | 2018 |
Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity.
Topics: Amphetamine-Related Disorders; Cocaine-Related Disorders; Drug-Related Side Effects and Adverse Reac | 2013 |
A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England.
Topics: Adolescent; Adult; Amphetamines; Birth Weight; Case-Control Studies; Cohort Studies; Drug-Related Si | 2004 |
Pharmacological content of tablets sold as "ecstasy": results from an online testing service.
Topics: Drug Contamination; Drug-Related Side Effects and Adverse Reactions; Hallucinogens; Humans; Illicit | 2006 |
A tale of two Es.
Topics: Alcoholic Intoxication; Amphetamine-Related Disorders; Cause of Death; Community Participation; Drug | 2006 |
Drug-related harm: a complex and difficult concept to scale.
Topics: Catha; Drug-Related Side Effects and Adverse Reactions; Hallucinogens; Harm Reduction; Humans; N-Met | 2007 |
Caveat emptor: editors beware.
Topics: Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug-Related Side Effects and A | 2001 |
Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity.
Topics: Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Corpus Striatum; Cytoplasm; Cytoplasmic | 2002 |